APO RESEARCH · REPORT
Prostate Cancer Diagnostics
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Product & engineering
Understand the product.
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
Selected research
Industry Research
Prostate Cancer Diagnostics Industry Research Report 2026
Market perspective
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.
Read the full market overview
Report Scope
This report quantifies the global Prostate Cancer Diagnostics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Prostate Cancer Diagnostics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Prostate Cancer Diagnostics Market by Company
OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics
Prostate Cancer Diagnostics Segment by Type
Tumor Biomarker Tests
Imaging
Biopsy
Other
Prostate Cancer Diagnostics Segment by Application
Age Below 55
Age 55-75
Age Above 75
Prostate Cancer Diagnostics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Prostate Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tumor Biomarker Tests
- Imaging
- Biopsy
- Other
Applications
- Age Below 55
- Age 55-75
- Age Above 75
Companies covered
- OPKO
- Genomic Health
- Abbott
- Beckman Coulter
- Siemens Healthcare
- bioMeriux
- Roche
- MDx Health
- DiaSorin
- Myriad Genetics
- Ambry Genetics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Prostate Cancer Diagnostics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tumor Biomarker Tests
- 2.2.3 Imaging
- 2.2.4 Biopsy
- 2.2.5 Other
- 2.3 Prostate Cancer Diagnostics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Age Below 55
- 2.3.3 Age 55-75
- 2.3.4 Age Above 75
- 2.4 Assumptions and Limitations
3 Prostate Cancer Diagnostics Breakdown Data by Type
- 3.1 Global Prostate Cancer Diagnostics Historic Market Size by Type (2021-2026)
- 3.2 Global Prostate Cancer Diagnostics Forecasted Market Size by Type (2027-2032)
4 Prostate Cancer Diagnostics Breakdown Data by Application
- 4.1 Global Prostate Cancer Diagnostics Historic Market Size by Application (2021-2026)
- 4.2 Global Prostate Cancer Diagnostics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Prostate Cancer Diagnostics Market Perspective (2021-2032)
- 5.2 Global Prostate Cancer Diagnostics Growth Trends by Region
- 5.2.1 Global Prostate Cancer Diagnostics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Prostate Cancer Diagnostics Historic Market Size by Region (2021-2026)
- 5.2.3 Prostate Cancer Diagnostics Forecasted Market Size by Region (2027-2032)
- 5.3 Prostate Cancer Diagnostics Market Dynamics
- 5.3.1 Prostate Cancer Diagnostics Industry Trends
- 5.3.2 Prostate Cancer Diagnostics Market Drivers
- 5.3.3 Prostate Cancer Diagnostics Market Challenges
- 5.3.4 Prostate Cancer Diagnostics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Prostate Cancer Diagnostics Players by Revenue
- 6.1.1 Global Top Prostate Cancer Diagnostics Players by Revenue (2021-2026)
- 6.1.2 Global Prostate Cancer Diagnostics Revenue Market Share by Players (2021-2026)
- 6.2 Global Prostate Cancer Diagnostics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Prostate Cancer Diagnostics Head Office and Area Served
- 6.4 Global Prostate Cancer Diagnostics Players, Product Type & Application
- 6.5 Global Prostate Cancer Diagnostics Manufacturers Established Date
- 6.6 Global Prostate Cancer Diagnostics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Prostate Cancer Diagnostics Market Size (2021-2032)
- 7.2 North America Prostate Cancer Diagnostics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Prostate Cancer Diagnostics Market Size by Country (2021-2026)
- 7.4 North America Prostate Cancer Diagnostics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Prostate Cancer Diagnostics Market Size (2021-2032)
- 8.2 Europe Prostate Cancer Diagnostics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Prostate Cancer Diagnostics Market Size by Country (2021-2026)
- 8.4 Europe Prostate Cancer Diagnostics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Prostate Cancer Diagnostics Market Size (2021-2032)
- 9.2 Asia-Pacific Prostate Cancer Diagnostics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Prostate Cancer Diagnostics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Prostate Cancer Diagnostics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Prostate Cancer Diagnostics Market Size (2021-2032)
- 10.2 South America Prostate Cancer Diagnostics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Prostate Cancer Diagnostics Market Size by Country (2021-2026)
- 10.4 South America Prostate Cancer Diagnostics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Prostate Cancer Diagnostics Market Size (2021-2032)
- 11.2 Middle East & Africa Prostate Cancer Diagnostics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 OPKO
- 12.1.1 OPKO Company Information
- 12.1.2 OPKO Business Overview
- 12.1.3 OPKO Revenue in Prostate Cancer Diagnostics Business (2021-2026)
- 12.1.4 OPKO Prostate Cancer Diagnostics Product Portfolio
- 12.1.5 OPKO Recent Developments
- 12.2 Genomic Health
- 12.2.1 Genomic Health Company Information
- 12.2.2 Genomic Health Business Overview
- 12.2.3 Genomic Health Revenue in Prostate Cancer Diagnostics Business (2021-2026)
- 12.2.4 Genomic Health Prostate Cancer Diagnostics Product Portfolio
- 12.2.5 Genomic Health Recent Developments
- 12.3 Abbott
- 12.3.1 Abbott Company Information
- 12.3.2 Abbott Business Overview
- 12.3.3 Abbott Revenue in Prostate Cancer Diagnostics Business (2021-2026)
- 12.3.4 Abbott Prostate Cancer Diagnostics Product Portfolio
- 12.3.5 Abbott Recent Developments
- 12.4 Beckman Coulter
- 12.4.1 Beckman Coulter Company Information
- 12.4.2 Beckman Coulter Business Overview
- 12.4.3 Beckman Coulter Revenue in Prostate Cancer Diagnostics Business (2021-2026)
- 12.4.4 Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
- 12.4.5 Beckman Coulter Recent Developments
- 12.5 Siemens Healthcare
- 12.5.1 Siemens Healthcare Company Information
- 12.5.2 Siemens Healthcare Business Overview
- 12.5.3 Siemens Healthcare Revenue in Prostate Cancer Diagnostics Business (2021-2026)
- 12.5.4 Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
- 12.5.5 Siemens Healthcare Recent Developments
- 12.6 bioMeriux
- 12.6.1 bioMeriux Company Information
- 12.6.2 bioMeriux Business Overview
- 12.6.3 bioMeriux Revenue in Prostate Cancer Diagnostics Business (2021-2026)
- 12.6.4 bioMeriux Prostate Cancer Diagnostics Product Portfolio
- 12.6.5 bioMeriux Recent Developments
- 12.7 Roche
- 12.7.1 Roche Company Information
- 12.7.2 Roche Business Overview
- 12.7.3 Roche Revenue in Prostate Cancer Diagnostics Business (2021-2026)
- 12.7.4 Roche Prostate Cancer Diagnostics Product Portfolio
- 12.7.5 Roche Recent Developments
- 12.8 MDx Health
- 12.8.1 MDx Health Company Information
- 12.8.2 MDx Health Business Overview
- 12.8.3 MDx Health Revenue in Prostate Cancer Diagnostics Business (2021-2026)
- 12.8.4 MDx Health Prostate Cancer Diagnostics Product Portfolio
- 12.8.5 MDx Health Recent Developments
- 12.9 DiaSorin
- 12.9.1 DiaSorin Company Information
- 12.9.2 DiaSorin Business Overview
- 12.9.3 DiaSorin Revenue in Prostate Cancer Diagnostics Business (2021-2026)
- 12.9.4 DiaSorin Prostate Cancer Diagnostics Product Portfolio
- 12.9.5 DiaSorin Recent Developments
- 12.10 Myriad Genetics
- 12.10.1 Myriad Genetics Company Information
- 12.10.2 Myriad Genetics Business Overview
- 12.10.3 Myriad Genetics Revenue in Prostate Cancer Diagnostics Business (2021-2026)
- 12.10.4 Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
- 12.10.5 Myriad Genetics Recent Developments
- 12.11 Ambry Genetics
- 12.11.1 Ambry Genetics Company Information
- 12.11.2 Ambry Genetics Business Overview
- 12.11.3 Ambry Genetics Revenue in Prostate Cancer Diagnostics Business (2021-2026)
- 12.11.4 Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
- 12.11.5 Ambry Genetics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst